ERBB2 and invasive breast carcinoma: In a recent study, HER2 DIA connectivity showed the strongest association among other prognostic parameters with pathologic complete response in a cohort of HER2+ invasive breast carcinomas treated with anti-HER2 agents in the neoadjuvant setting [103].